Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: A primer

Pharmacotherapy

Volumn 33, Issue 3, 2013, Pages 304-318

  Chen, Jack J ^a   Dashtipour, Khashayar ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abobotulinumtoxina; Botulinum toxin; Incobotulinumtoxina; Onabotulinumtoxina; Rimabotulinumtoxinb

Indexed keywords

4 AMINOPYRIDINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CBTX A; CNBTX A; MUSCLE RELAXANT AGENT; NEURONOX; NEUROTOXIN; NEUTRALIZING ANTIBODY; PLACEBO; RT 001; SNARE PROTEIN; SPASMOLYTIC AGENT; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANUS FISSURE; BIOEQUIVALENCE; BLEEDING; BLEPHAROSPASM; BOTULISM; CERVICAL DYSTONIA; DENERVATION; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STORAGE; DRUG SYNTHESIS; DYSPHAGIA; DYSPHONIA; ECCHYMOSIS; ESOPHAGUS ACHALASIA; ESOPHAGUS FUNCTION DISORDER; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEMATOMA; HUMAN; HYPERACTIVITY; HYPERHIDROSIS; HYPERSALIVATION; IMMUNITY; IMMUNOGENICITY; INJECTION SITE DISCOMFORT; INJECTION SITE REACTION; LD 50; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NEURODERMATITIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; OVERACTIVE BLADDER; PARESIS; PATIENT SAFETY; PHARMACEUTICAL EQUIVALENCE; PROSTATE HYPERTROPHY; PROTEIN CLEAVAGE; QUALITY CONTROL; RECOMMENDED DRUG DOSE; RETROGRADE NERVE FIBER TRANSPORT; REVIEW; SPASTICITY; STRABISMUS; TARDIVE DYSKINESIA; TEMPOROMANDIBULAR JOINT DISORDER; TENDINITIS; TIC; TOXIN ANALYSIS; TREATMENT INDICATION; TREMOR; XEROSTOMIA;

BOTULINUM TOXINS; BOTULINUM TOXINS, TYPE A; CLINICAL MEDICINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG LABELING; HUMANS;

EID: 84875456301     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1196     Document Type: Review

References (76)

1. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981;33:155-88.
2. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 2007;29:1761-8.
3. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain 2002;18(Suppl 6):S119-24.
4. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001;8(Suppl 5):21-9.
5. Center for Food Security and Public Health. Botulism. Ames, IA: College of Veterinary Medicine, Iowa State University; 2005. Available at http://www.cfsph.iastate.edu/Factsheets/pdfs/botulism.pdf. Accessed January 15, 2013.
6. Wortzman MS, Pickett A. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use. Aesthet Surg J 2009;6(Suppl):S34-S42.
7. Botox (onabotulinumtoxinA) [package insert]. Irvine, CA: Allergan, Inc.; 2011.
8. Dysport (abobotulinumtoxinA) [package insert]. Wrexham, UK: Ipsen Biopharm, Ltd.; 2010.
9. Xeomin (incobotulinumtoxinA) [package insert]. Greensboro, NC: Merz Pharmaceuticals, LLC; 2011.
10. Myobloc (rimabotulinumtoxinB) [package insert]. South San Francisco, CA: Solstice Neurosciences, Inc.; 2010.
11. Pickett A, Perrow K. Formulation composition of botulinum toxins in clinical use. J Drugs Dermatol 2010;9(9):1085-91.
12. Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1707-14.
13. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1699-706.
14. Simpson DM, Gracies JM, Graham HK, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence- based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-8.
15. Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010;74:336-43.
16. Love SC, Novak I, Kentish M, et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol 2010;17(Suppl 2):9-37.
17. Fehlings D, Novak I, Berweck S, Hoare B, Stott NS, Russo RN. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. Eur J Neurol 2010;17(Suppl 2):38-56.
18. Olver J, Esquenazi A, Fung VS, Singer BJ, Ward AB. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol 2010;17(Suppl 2):57-73.
19. Sheean G, Lannin NA, Turner-Stokes L, Rawicki B, Snow BJ. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol 2010;17(Suppl 2):74-93.
20. Novak I, Campbell L, Boyce M, Fung VS. Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. Eur J Neurol 2010;17(Suppl 2):94-108.
21. Reddihough D, Erasmus CE, Johnson H, McKellar GM, Jongerius PH. Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement. Eur J Neurol 2010;17(Suppl 2):109-21.
22. Rawicki B, Sheean G, Fung VS, Goldsmith S, Morgan C, Novak I. Botulinum toxin assessment, intervention and aftercare for paediatric and adult niche indications including pain: international consensus statement. Eur J Neurol 2010;17(Suppl 2):122-34.
23. Esquenazi A, Mayer NH, Elia AE, Albanese A. Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon 2009;54:634-8.
24. Elia AE, Filippini G, Calandrella D, Albanse A. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord 2009;24:801-12.
25. Zhang T, Adatia A, Zarin W, et al. The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis. Inflammopharmacology 2011;19:21-34.
26. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011;12: CD005493.
27. Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006;296:2476-9.
28. Pickett A, Mewies M. Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol 2009;61:149-50.
29. Hunt T, Clarke K. Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test. J Am Acad Dermatol 2008;58:517-8.
30. Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm 2008;115:559-65.
31. Tsai YC, Maditz R, Kuo CL, et al. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci U S A 2010;107:16554-9.
32. Adler S, Bicker G, Bigalke H, et al. The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. Altern Lab Anim 2010;38:315-30.
33. Sesardic D, Leung T, Gaines Das R. Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals 2003;31:265-76.
34. McLellan K, Das RE, Ekong TA, Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996;34:975-85.
35. Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med 1994;87:719.
36. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988;3:333-5.
37. Frevert J. Content of botulinum neurotoxin in Botox(R)/Vistabel( R), Dysport(R)/Azzalure(R), and Xeomin(R)/Bocouture(R). Drugs R D 2010;10:67-73.
38. Pickett A, O'Keeffe R, Panjwani N. The protein load of therapeutic botulinum toxins. Eur J Neurol 2007;14:e11.
39. Pickett A. Consistent biochemical data are essential for comparability of botulinum toxin type A products. Drugs R D 2011;11:97-8; author reply 98-9.
40. Sesardic D. Is it possible to accurately determine content of botulinum neurotoxin type A in drug products? Drugs R D 2010;10:91-2.
41. Setler P. The biochemistry of botulinum toxin type B. Neurology 2000;55(Suppl 5):S22-8.
42. Dressler D, Mander G, Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox[R]) and incobotulinumtoxinA (Xeomin [R]) in an LD50 assay. J Neural Transm 2012;119:13-5.
43. Hexsel D, Brum C, do Prado DZ, et al. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial. J Am Acad Dermatol 2012;67:226-32.
44. Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin 2009;25:1573-84.
45. Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg 2009;35:1-8.
46. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers product summaries. J Clin Pharm Ther 2007;32:387-402.
47. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004;19 (Suppl 19):S129-36.
48. Roche N, Schnitzler A, Genet FF, Durand MC, Bensmail D. Undesirable distant effects following botulinum toxin type a injection. Clin Neuropharmacol 2008;31:272-80.
49. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004;140:1351-4.
50. Pickett A. Dysport: pharmacological properties and factors that influence toxin action. Toxicon 2009;54:683-9.
51. Wagman J, Bateman JB. Botulinum type A toxin: properties of a toxic dissociation product. Arch Biochem Biophys 1953;45:375-83.
52. Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 2011;57:555-65.
53. Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 2009;40:374-80.
54. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999;246:265-74.
55. Benecke R. Clinical relevance of botulinum toxin immunogenicity. Biodrugs 2012;26:e1-e9.
56. Schulte-Baukloh H, Bigalke H, Miller K, et al. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 2008;70:133-6.
57. Pickett A, Rosales RL. New trends in the science of botulinum toxin-A as applied in dystonia. Int J Neurosci 2011;121(Suppl 1):22-34.
58. Jankovic J, Hunter C, Dolimbek BZ, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006;67:2233-5.
59. Dressler D, Bigalke H. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. J Neurol 2005;252:904-7.
60. Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol 2008;45:3878-88.
61. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol 2007;44:1029-41.
62. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 2010;4:325-32.
63. Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 2009;32:213-8.
64. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003;60:1186-8.
65. Coleman C, Hubble J, Schwab J, Beffy J, Picaut P, Morte C. Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA (Dysport). Int J Neurosci 2012;122:358-62.
66. Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Mov Disord 2004;19(Suppl 8):S68-S84.
67. Francisco GE. Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil 2004;83(Suppl 10):S30-7.
68. Trindade De Almeida AR, Secco LC, Carruthers A. Handling botulinum toxins: an updated literature review. Dermatol Surg 2011;37:1553-65.
69. Liu A, Carruthers A, Cohen JL, et al. Recommendations and current practices for the reconstitution and storage of botulinum toxin type A. J Am Acad Dermatol 2012;67:373-8.
70. Li M, Goldberger BA, Hopkins C. Fatal case of BOTOXrelated anaphylaxis? J Forensic Sci 2005;50:169-72.
71. Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005;53:407-15.
72. LeWitt PA, Trosch RM. Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection. Mov Disord 1997;12:1064-7.
73. Atkinson WL, Pickering LK, Schwartz B, Weniger BG, Iskander JK, Watson JC, Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 2002;51(RR-2): 1-35.
74. FDA response to citizen petition on botulinum. April 30, 2009. http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafety- InformationforHeathcareProfessionals/UCM143989.pdf. Accessed January 15, 2013.
75. Adler M, MacDonald DA, Sellin LC, Parker GW. Effect of 3, 4- diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. Toxicon 1996;34:237-49.
76. Pickett A, Perrow K. Towards new uses of botulinum toxin as a novel therapeutic tool. Toxins (Basel) 2011;3:63-81.